Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30932262 | 0.77 | PABPC1 (0.47) | ERBB2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL16643897 | 0.76 | ERBB2 (0.37) | ERBB2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL30932231 | 0.75 | PIK3CG (0.46) | ERBB2MEN1KMT2AKDM4E | |
| SCHEMBL9700727 | 0.75 | PIK3CG (0.46) | ERBB2MEN1KMT2AKDM4E | |
| SCHEMBL30932254 | 0.75 | KDM4E (0.52) | ERBB2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL19075884 | 0.75 | NQO2 (0.57) | ERBB2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL30932232 | 0.75 | NQO2 (0.57) | ERBB2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL19470934 | 0.74 | NQO2 (0.52) | ERBB2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL19521912 | 0.73 | ERBB2 (0.35) | ERBB2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1258591 | 0.72 | MAPT (0.53) | ERBB2MEN1NPC1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590165-B2 | Antibody drug conjugates | SORRENTO THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170224835-A1 | Antibody Drug Conjugates | SORRENTO THERAPEUTICS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170190736-A1 | Antibody Drug Conjugates | SORRENTO THERAPEUTICS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590165-B2 | Antibody drug conjugates | STT3B, STT3A, HSD17B14 | ERBB2 1598/4885MEN1 4065/4885NPC1 46/4885 |
| US-20170190736-A1 | Antibody Drug Conjugates | STT3B, STT3A, HSD17B14 | ERBB2 1598/4885MEN1 4065/4885NPC1 46/4885 |
| US-20170224835-A1 | Antibody Drug Conjugates | DARS1, CD38, AADAC | ERBB2 113/4885MEN1 3485/4885NPC1 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.